IPO keeps Adaptimmune in immunotherapy race as bets pass $1.5bn
This article was originally published in Scrip
Adaptimmune has become the latest immunotherapy company to raise a large chunk of cash on a US stock exchange, raising an estimated $175m net of expenses through a 6 May offering of American Depositary Shares on Nasdaq. In an area of huge potential but little clinically-proven differentiation, the new money may provide a sufficient financial springboard for the Oxford, UK-based company to throw cash at product development, slugging it out with well-backed US-based firms such as Bellicum Pharmaceuticals, Kite Pharma and Juno Therapeutics, as well as with established competitors such as Novartis.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.